(Total Views: 57)
Posted On: 11/04/2019 8:00:43 AM
Post# of 15442
$TNXP News Article - Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya for PTSD, Following FDA Meeting https://marketwirenews.com/news-releases/toni...31751.html
(0)
(0)
My Twitter: WhyteStocks
